News headlines about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat negative on Wednesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.523544447223 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- GLMD Arrests Investor Attention, SAGE Excited, GEMP On Close Watch (markets.businessinsider.com)
- Non Alcoholic Fatty Liver Disease Market Pipeline Review H1 Overview with Drug Profiles, Symptoms, Treatment … (businessinvestor24.com)
- Dyslipidemia Market Pipeline Revive H1 Therapeutics, 2018 Stage of Development, Companies and Product Description (thecleantechnology.com)
- These Will Blow Your Mind: Houston American Energy Corp. (NYSE:HUSA), Gemphire Therapeutics Inc. (NASDAQ … (thestreetpoint.com)
- Hair-Raising Facts to Know about Company’s 50 days simple moving average (SMA50): Cherokee Inc. (NASDAQ … (stocksnewspoint.com)
GEMP traded down $0.20 on Wednesday, hitting $7.02. 5,533 shares of the stock were exchanged, compared to its average volume of 198,668. The stock has a market capitalization of $92.79 million, a price-to-earnings ratio of -2.17 and a beta of 4.29. The company has a quick ratio of 5.57, a current ratio of 5.57 and a debt-to-equity ratio of 0.37. Gemphire Therapeutics has a 12 month low of $4.75 and a 12 month high of $21.59.
Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.05. sell-side analysts anticipate that Gemphire Therapeutics will post -2.57 EPS for the current fiscal year.
GEMP has been the subject of several research reports. Raymond James assumed coverage on shares of Gemphire Therapeutics in a research report on Wednesday, May 16th. They issued an “outperform” rating and a $22.00 price objective for the company. Zacks Investment Research raised shares of Gemphire Therapeutics from a “sell” rating to a “buy” rating and set a $7.50 price objective on the stock in a research note on Thursday, February 15th. Finally, ValuEngine raised shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $22.64.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.